HCV NS3 Genotype-3
Description
Product Specs
Product Science Overview
Hepatitis C Virus (HCV) is a significant global health concern, infecting millions of people worldwide. Among the various genotypes of HCV, genotype 3 is particularly prevalent and poses unique challenges in terms of treatment and management. The non-structural protein 3 (NS3) of HCV plays a crucial role in the virus’s life cycle, including replication and pathogenesis. The recombinant form of NS3, specifically the amino acid sequence 1356-1459, has been extensively studied for its potential in diagnostic and therapeutic applications.
The preparation of recombinant NS3 protein involves several key steps. Initially, the gene encoding the NS3 protein is amplified using polymerase chain reaction (PCR) techniques. The amplified gene is then cloned into a suitable expression vector, such as pET-32a, which is subsequently introduced into a bacterial host, typically Escherichia coli (E. coli) BL21ply* . The bacterial cells are cultured under optimal conditions to express the recombinant protein. Following expression, the protein is purified using affinity chromatography methods, such as Nickel-affinity chromatography, to achieve high purity levels . The purity and expression levels are confirmed through techniques like western blotting and CD spectroscopy .
The NS3 protein of HCV exhibits protease and helicase activities, which are essential for viral replication. The protease activity involves the cleavage of the viral polyprotein into functional units, while the helicase activity is responsible for unwinding the viral RNA . The recombinant NS3 protein retains these enzymatic activities, making it a valuable tool for studying the virus’s life cycle and for screening potential antiviral drugs. Molecular dynamics simulations and structural analyses have been employed to understand the active sites of the NS3 protease and its interactions with various inhibitors . These studies have provided insights into the protein’s catalytic mechanisms and have facilitated the design of more effective antiviral therapies .
